Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-767-1 | CAS number: 7722-88-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
There were no studies available on tetrasodium pyrophosphate. The reproductive toxicity endpoint has been addressed with the following data adaptations:
Section 8.7.1. Adaptation
According to Annex VIII, Section 8.7.1, Column 2 of Regulation (EC) No. 1907/2006, a screening for reproductive/developmental toxicity study does not need to be conducted if a prenatal development toxicity study is available. A developmental toxicity study on tetrasodium pyrophosphate and the analogue substance disodium dihydrogenpyrophosphate is included in IUCLID Section 7.8.2 of this dossier and therefore a screening study is not considered to be scientifically justified.
Section 8.7.2. Adaptation
The standard requirement for chemicals manufactured or imported into the EU in quantities of >1,000 an extended one generation reproductive toxicity test (EOGRTS). According to the Integrated Testing Strategy (ITS) proposed in the ECHA guidance document on the information requirements and chemical safety assessment, Chapter R. 7a: Endpoint specific guidance, Section 7.6.6, if there is sufficient data to permit a robust conclusion on reproductive toxicity testing then no further testing will be required. The justification for not conducting a two-generation study is based on the evaluation of existing data in laboratory animals, available data on similar or parent compounds, historical data and general characteristics of the test material.
For the purpose of assessing the risk of reprotoxicity the following substances are considered to be similar enough to facilitate read across:
- disodium dihydrogenpyrophosphate (EC No. 231-835-0)
- trisodium hydrogen diphosphate (EC No. 238-735-6)
- tetrasodium pyrophosphate (EC No. 231-767-1)
- tetrapotassium pyrophosphate (EC No. 230-785-7)
LABORATORY STUDIES
- Negative In vitro mutagenicity and genotoxicity evidence suggests a low potential for germ cell mutagenicity. The following studies have been conducted on Na, and K pyrophosphates: Bacterial Reverse Mutation Assay; AMES (OECD 471) and In vitro cytogenicity study in mammalian cells (OECD 473). Whilst these studies look specifically at the effects in somatic cell lines the results are still relevant to the potential of the test material to induce mutagenicity in germ cell lines.
- Negative in vivo genotoxicity data. The results of a dominant lethal assay conducted on disodium dihydrogenpyrophosphate are presented in Section 7.8.2 of this dossier. This study looks at the potential of a chemical substance to induce chromosomal aberrations in the germ cells of rats. As no effects are noted this can be used as part of the evidence against performing studies to investigate the effects on reprotoxicity.
-Developmental toxicity / teratogenicity studies similar to OECD 414 have been conducted on the following substances on behalf of the United States Food and Drug Administration; disodium dihydrogenpyrophosphate (sodium acid pyrophosphate) and tetrasodium pyrophosphate. The studies were conducted in four laboratory animal models; rat, mouse, hamster and rabbit. A range of dose levels up to a high dose of 335 mg/kg bw (mouse, disodium dihydrogenpyrophosphate), 169 mg/kg bw (rat, disodium dihydrogenpyrophosphate), 166 mg/kg bw (hamster, disodium dihydrogenpyrophosphate), 128 mg/kg bw (rabbit, disodium dihydrogenpyrophosphate), 130 mg/kg bw (mouse, tetrasodium pyrophosphate) and 138 mg/kg bw (rat, tetrasodium pyrophosphate) were used. The material was administered by oral intubation for ten consecutive days for rats and mice covering the gestation days 6 to 15. Although the studies were conducted prior to the implementation of Good Laboratory Practice, the study design and content were of sufficient standard to allow meaningful evaluation. The results showed no evidence of developmental toxicity to the foetus of any species or any other adverse effects to the foetus or mother at any dose level. It can therefore be concluded that sodium and potassium orthophosphates are not developmental toxicants at relatively high levels.
The lack of effects on maternal toxicity or offspring development at dose levels well in excess of normal human exposure suggests that sodium and potassium pyrophosphates are not a significant risk to the reproductive process and further studies are unlikely to show any significant effects.
GENERAL DISCUSSION
The pyrophosphate ion is the simplest form of a condensed phosphate group. A condensed phosphate anion has one or several P-O-P bonds. As the pyrophosphate only contains two phosphate groups, both of the phosphorus ions are classed as terminal phosphorus. The pyrophosphate can undergo ionisation with loss of H+ from each of the two –OH group groups on each P and can therefore occur in the -1, -2, -3 or -4 state. The degree of ionisation is dependent on upon the associated cations and the ambient pH (if in solution). As pyrophosphates are ionic in nature they will readily dissociate into their cations and anions in solution.
Sodium and potassium cations are not considered to pose a risk of reprotoxicity as they are essential micronutrients that are well regulated by the homeostatic mechanisms in the body. In addition, the recommended daily intakes of sodium and potassium for young adults are 1500 mg/day/person and 4700 mg/day/person respectively (1). These levels are well above the levels that would be expected in a reprotoxicity study and therefore the sodium or potassium cation can be discounted from further discussion.
The pyrophosphate anion is hydrolysed to orthophosphate by ubiquitous alkaline phosphatase activity. Orthophosphate then goes on to take part in various physiological processes. The World Health Organisation, reports that the maximum tolerable daily intake (MTDI) of phosphates is 70 mg/kg bw (2), this value is considered to be well below that observed for developmental toxicity and as such human exposure is likely to be considerably less that the level required for reprotoxicity testing.
Sodium and potassium pyrophosphates are frequently used as food additives (the EU food reference / INS number for tetrasodium pyrophosphate is E450 ii). The contribution of food supplements to phosphorus intake is low. No evidence exists to show that sodium or potassium pyrophosphates are likely to pose a risk of reproductive or developmental toxicity. The main toxicological finding in feeding studies with high levels of phosphates is nephrocalcinosis (the rat is known to be more susceptible to these effects (2, see also IUCLID section 7.5.), these effects are not considered to be relevant to reproductive toxicity.
In conclusion, an additional in vivo reproduction study in the rat is unlikely to result in providing further evidence of reproductive toxicity as the existing studies have demonstrated a lack of effect at dose levels well in excess of expected human exposure. A study would therefore be scientifically and ethically unjustified.
(1) Dietary Reference Intakes for Water, Potassium, Sodium, Chloride and sulphate. www.nap.edu. The National Academies. U.S.A.
(2)Evaluation of certain food additives and contaminants. Twenty-sixth report of the joint FAO/WHO expert committee of food additives. World Health Organisation. Technical Report Series 683. 1982. ISBN92 4 120683 7
Effects on developmental toxicity
Description of key information
Under the conditions of the study on tetrasodium pyrophosphate, administered to pregnant mice for 10 days up to a dose level of 130 mg/kg bw showed no maternal or developmental toxicity. The NOAEL for both maternal and fetotoxicity is > 130 mg/kg bw.
Tetrasodium pyrophosphate was also administered to pregnant rats for 10 days up to a dose level of 138 mg/kg bw showed no maternal or developmental toxicity. The NOAEL for both maternal and fetotoxicity is > 138 mg/kg bw.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 3/9/74 - 2/10/74
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Remarks:
- Meets generally accepted scientific standards with acceptable restrictions. Deficiencies: Food consumption not reported Uterine weights not determined One third used for visceral examination; should be 50% Test substance identification (Batch etc) missing No details on housing conditions/source of animals Administration only during periods of organogenesis, not until day before pregnancy
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- other: no data
- Deviations:
- not specified
- Principles of method if other than guideline:
- Adult female albino (Wistar derived stock) rats were mated with young adult males. Observation of a vaginal sperm plug was considered as Day 0 of gestation. Dosing by oral intubation with a control (Vehicle at level equivalent to group receiving the highest dose or aspirin at 250 mg/kg) or test article in a water suspension at 1.38, 6.41, 29.7 and 138.0 mg/kg was carried out daily on Days 6 to 15 of gestation. Observations of body weight, appearence, behaviour, and food consumption were performed. Daily room temperature was recorded. On Day 20 of gestation all dams underwent Caesarean section. Sex, number of corpora lutea, implantation sites, resorption sites and live/dead foetuses recorded. Body weights of live pups recorded. Urogenital tract of each dam examined for anatomical normality. All foetuses examined grossly for presence of external congenital abnormalities. One third foetuses of each litter underwent detailed visceral examination and the remaining two thirds were cleared in potassium hydroxide, stained with alizarin red S dye and examined for skeletal defects.
- GLP compliance:
- no
- Remarks:
- Study predates GLP
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Outbred
- Age at study initiation: No data
- Weight at study initiation: 215 - 221 g
- Fasting period before study: No data
- Housing: Individual housing in mesh bottom cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: No data
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 - 26.7
- Humidity (%): 62 - 76
IN-LIFE DATES: 3/9/74 - 2/10/74 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
VEHICLE: Water
- Amount of vehicle (if gavage): 1 mL/kg bw at doses equal to or below 250 mg/kg bw and 2 mL/kg at doses up to 500 mg/kg bw - Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- - Impregnation procedure: No data
- Proof of pregnancy: vaginal plug referred to as day 0 of pregnancy - Duration of treatment / exposure:
- 10 days (Day 6 to Day 15 of gestation)
- Frequency of treatment:
- Daily
- Duration of test:
- 20 days
- No. of animals per sex per dose:
- Table 1 Number of animals dosed
Material Dose (mg/kg) Total
Mated Pregnant
Sham 0.0 25 20
Aspirin 250.0 25 19
FDA 73-1 1.38 23 21
6.41 24 20
29.7 25 20
138.0 25 19 - Control animals:
- yes, sham-exposed
- other: positive control: 250 mg/kg aspirin
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Appearence, behaviour, food consumption and weight observed daily.
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights recorded on days 0, 6, 11, 15 and 20.
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: uterus and urogenital tract - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of resorptions: Yes - Fetal examinations:
- - External examinations: Yes: one third per litter
- Soft tissue examinations: Yes: one third per litter
- Skeletal examinations: Yes: two thirds per litter
- Head examinations: Yes: two thirds per litter - Statistics:
- No data
- Indices:
- No data
- Historical control data:
- No
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
- Dose descriptor:
- NOAEL
- Effect level:
- > 138 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: no effects observed
- Abnormalities:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
- Dose descriptor:
- NOAEL
- Effect level:
- > 138 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no effects observed
- Abnormalities:
- not specified
- Developmental effects observed:
- no
- Conclusions:
- Under the conditions of the study, the test material administered to pregnant rats for 10 days up to a dose level of 138 mg/kg bw showed no maternal or developmental toxicity. The NOAEL for both maternal and fetotoxicity is > 138 mg/kg bw.
Reference
Table 2 Reproduction data
Dose (mg/kg) |
Sham |
Aspirin |
1.38 |
6.41 |
29.7 |
138.0 |
Pregnancies |
|
|
|
|
|
|
Total No. |
20 |
19 |
21 |
20 |
20 |
19 |
Died or aborted (before Day 20) |
0 |
0 |
0 |
0 |
0 |
0 |
To term (on Day 20) |
20 |
19 |
21 |
20 |
20 |
19 |
Corpora Lutea |
|
|
|
|
|
|
Total no. |
244 |
258 |
267 |
263 |
249 |
248 |
Average/dam mated |
9.76 |
10.3 |
11.6 |
11.0 |
9.96 |
9.92 |
Live litters |
|
|
|
|
|
|
Total No.* |
20 |
19 |
21 |
20 |
20 |
19 |
Implant Sites |
|
|
|
|
|
|
Total No. |
228 |
225 |
240 |
249 |
237 |
232 |
Average/dam* |
11.4 |
11.8 |
11.4 |
12.5 |
11.9 |
12.2 |
Resorptions |
|
|
|
|
|
|
Total No* |
4 |
17 |
1 |
5 |
8 |
1 |
Dams with 1 or more sites resorbed |
2 |
8 |
1 |
4 |
6 |
1 |
Dams with all sites resorbed |
-- |
-- |
-- |
-- |
-- |
-- |
Per cent partial resorptions |
10.0 |
42.1 |
4.76 |
20.0 |
30.0 |
5.26 |
Per cent complete resorptions |
-- |
-- |
-- |
-- |
-- |
-- |
Live foetuses |
|
|
|
|
|
|
Total No |
224 |
208 |
239 |
244 |
229 |
231 |
Average/dam* |
11.2 |
11.0 |
11.4 |
12.2 |
11.5 |
12.2 |
Sex ratio (M/F) |
0.96 |
1.04 |
0.98 |
0.95 |
1.14 |
0.94 |
Dead Foetuses |
|
|
|
|
|
|
Total No.* |
-- |
-- |
-- |
-- |
-- |
-- |
Dams with 1 or more dead |
-- |
-- |
-- |
-- |
-- |
-- |
Dams with all dead |
-- |
-- |
-- |
-- |
-- |
-- |
Per cent partial dead |
-- |
-- |
-- |
-- |
-- |
-- |
Per cent all dead |
-- |
-- |
-- |
-- |
-- |
-- |
Average foetus weight (g) |
3.90 |
2.97 |
4.01 |
4.01 |
3.95 |
4.09 |
* Includes only those dams examined at term
** Positive control: 250 mg/kg
Table 3 Summary of skeletal findings
Findings |
Dose (mg/kg) |
|||||
Sham |
Aspirin |
4.1 |
19.0 |
88.3 |
410.0 |
|
Live foetuses examined (at term) |
156/20 |
145/19 |
165/21 |
169/20 |
163/20 |
160/19 |
Sternebrae |
|
|
|
|
|
|
Incomplete oss. |
20/12 |
86/18 |
36/14 |
19/11 |
46/15 |
7/5 |
Scrambled |
|
|
|
|
|
|
Bipartite |
|
3/2 |
1/1 |
|
|
|
Fused |
|
|
|
|
|
|
Extra |
|
|
|
|
|
|
Missing |
2/2 |
117/19 |
9/7 |
4/3 |
15/9 |
|
Other |
|
|
|
|
|
|
Ribs |
|
|
|
|
|
|
Incomplete oss. |
3/2 |
|
|
2/1 |
|
|
Fused/split |
|
1/1 |
|
|
|
|
Wavy |
21/9 |
55/16 |
25/11 |
23/8 |
24/13 |
13/9 |
Less than 12 |
1/1 |
|
|
|
|
|
More than 13 |
|
110/17 |
5/1 |
|
1/1 |
1/1 |
Other |
|
|
|
|
|
|
Vertebrae |
|
|
|
|
|
|
Incomplete oss. |
6/4 |
64/17 |
4/2 |
3/2 |
2/2 |
|
Scrambled |
|
|
|
|
|
|
Fused |
|
|
|
|
|
|
Extra ctrs. oss. |
|
|
|
|
|
|
Scoliosis |
|
|
|
|
|
|
Tail defects |
|
|
|
|
|
|
Other |
|
|
|
|
|
|
Skull |
|
|
|
|
|
|
Incomplete closure |
32/12 |
48/14 |
19/12 |
27/11 |
17/7 |
18/9 |
Missing |
|
|
|
|
|
|
Craniostosis |
|
|
|
|
|
|
Other |
|
|
|
|
|
|
Extremities |
|
|
|
|
|
|
Incomplete oss. |
1/1 |
4/3 |
|
|
|
|
Missing |
|
|
|
|
|
|
Extra |
|
|
|
|
|
|
Miscellaneous |
|
|
|
|
|
|
Hyoid; missing |
16/8 |
45/15 |
10/8 |
17/9 |
17/7 |
10/9 |
Hyoid; reduced |
29/14 |
9/6 |
19/10 |
19/9 |
13/7 |
28/10 |
* Numerator = Number of foetuses affected; Denominator = Number of litters affected
** Positive control: 250 mg/kg
Table 4 Summary of soft tissue abnormalities
Material |
Dose level (mg/kg) |
Dam |
Number of pups |
Description |
Aspirin |
250.0 |
43634 |
1 |
Encephalomeningocele; encephalomyelocele |
|
|
43639 |
1 |
Gastroschisis |
|
|
43645 |
1 |
Hydrocephalus |
|
|
43654 |
4 |
Encephalomyelocele |
|
|
43655 |
1 |
Encephalomyelocele |
FDA 73-1 |
6.41 |
43707 |
1 |
Hydrocephalus; cleft palate |
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 138 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Two key studies (One study report, two different test animals) are available to assess the teratogenic potential of tetrasodium pyrophosphate (Bailey, 1974 ) in mice and rats. This study is considered to be adequate to fulfil this endpoint. In addition supporting data on the analogous substance disodium dihydrogenpyrophosphate is provided to support a lack of developmental toxicity potential for sodium and potassium pyrophosphates.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
There are no structural alerts to suggest that tetrasodium pyrophosphate is a developmental toxicant. The data presented are considered to adequately address this endpoint for the purpose of human risk assessment.
Justification for classification or non-classification
Tetrasodium pyrophosphate is not known nor presumed to be a human reproductive toxicant. In addition, based on knowledge of the use of the substance reproductive toxicity is not suspected.
No maternal or developmental toxicity was observed in the teratogenicity studies performed on tetrasodium pyrophosphate and there is no evidence to suggest that tetrasodium pyrophosphate will have any effect on lactation.
It is not considered to be scientifically justified to further investigate the effects of tetrasodium pyrophosphate on reprotoxicity, developmental or maternal toxicity and as such no classification is proposed for this endpoint and no further studies are deemed necessary.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.